HemaFlo Therapeutics, a private biotech company based in Carlsbad, Calif, has appointed Michael A. Martino as President, CEO and Board Director. Martino joined as President and CEO of Ambit Biosciences after its acquisition by Daiichi Sankyo in 2014.
HemaFlo Therapeutics is developing a platform of Drag Reducing Polymers (DRPs), which has applicability in a number of acute and chronic diseases associated with decreased tissue perfusion due to reduced blood flow.
“Martino’s experience is vital to HemaFlo as we take the next steps to accelerate the development of NephroFlow, our lead product for the treatment of acute kidney injury,” commented HemaFlo’s founder Dale Peterson.
“Developing an innovative therapy like NephroFlow that has the potential to benefit millions of patients while building HemaFlo into a vibrant company makes this an exciting opportunity for me,” stated Martino.
Prior to Ambit, Martino was a co-founder and CEO of Arzeda, a synthetic biology company that he helped spin out of the University of Washington. From 1998 to 2007, he served as President, CEO and Board Director of Sonus Pharmaceuticals, a publicly traded oncology company.